Novartis has re-shaped itself as a pure-play innovative-medicines company, betting on the complement (iptacopan) and radioligand-therapy platforms after divesting Sandoz. Its rare-renal and complement franchise overlaps directly with AXLRx's PNH and IgA nephropathy coverage.
United States — Fabhalta covered via specialty pharmacy; complement franchise leverages the Soliris/Ultomiris access precedent.
United Kingdom — NICE appraisals ongoing; Cosentyx and Kisqali NHS-commissioned.
GCC (Gulf) — SFDA registration underway for the complement portfolio; oncology assets exposed to Gulf tender dynamics.
The ATTR-CM vs ATTR-PN split, the wild-type/hereditary divide, and why Tc-PYP scintigraphy, not biopsy, is now the diagnostic gate for a largely undiagnosed population.
HAE pathophysiology, the Type I/II split, attack burden and the diagnostic-delay problem that defines the US in-market landscape.
2023 · Acquisition — Chinook Therapeutics ($3.2B) · IgA nephropathy
2024 · Acquisition — MorphoSys ($2.9B) · Myelofibrosis
2023 — Fabhalta (iptacopan) FDA approval in PNH · First oral monotherapy challenging the Alexion C5 duopoly
2023 — Sandoz spin-off completed · Full pivot to innovative medicines